Status:
COMPLETED
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2
Lead Sponsor:
NVP Healthcare
Conditions:
Healthy
Eligibility:
All Genders
19-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2
Detailed Description
pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2
Eligibility Criteria
Inclusion
- Male or female adults aged 19-45 years.
- BMI of \>18.5 kg/㎡ and \<27.0 kg/㎡ subject, weight more than 50kg.
- Voluntarily provided a witten consent to participate in this clinical study.
Exclusion
- Treatment with an investigational product (Phase I study or Biological study) within 3month preceeding the first dose of study medication.
- History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history
- Pregnant or lactating women.
Key Trial Info
Start Date :
April 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2019
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03802526
Start Date
April 3 2019
End Date
September 27 2019
Last Update
November 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Navipharm
Suwon, Gyeonggi-do, South Korea, 16209